

Special Issue

State of the Art on PET/CT and PET/MRI in Oncology

Message from the Guest Editor

The advancing development of personalized therapeutic concepts in the oncological context benefits from image-based precision medicine, where PET/CT and PET/MRI have proven to be valuable techniques for the early detection and precise localization of tumor lesions, accurate determination of tumor stage, and monitoring treatment response. With the ongoing development of individualized molecular therapy concepts, hybrid imaging has been gaining increasing diagnostic and clinical importance, as it provides the highest possible imaging information content compared to other radiological and nuclear medicine modalities. In addition, the exploration of various radiopharmaceutical agents has opened up novel possibilities for the in vivo molecular characterization of cancer. This Special Issue aims to highlight the role of hybrid imaging in cancer management, such as individualized diagnosis and therapeutic biomarker drug assessment, to provide clinicians with information to assist in the development of optimal treatment options for cancer. Therefore, we encourage researchers in the field to submit original articles and review papers to this Special Issue.

Guest Editor

Dr. Christian Philipp Reinert

Department of Radiology, Diagnostic and Interventional Radiology,
University Hospital Tübingen, Hoppe-Seyler-Str. 3, 72076 Tübingen,
Germany

Deadline for manuscript submissions

closed (1 June 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/174995

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).